Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Poor long-term outcomes and abnormal neurodegeneration biomarkers after military traumatic brain injury: the ADVANCE study.

Autor: Graham NS; Department of Brain Sciences, Imperial College London, London, UK.; UK Dementia Research Institute Centre for Care Research and Technology, London, UK., Blissitt G; Department of Brain Sciences, Imperial College London, London, UK.; Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK., Zimmerman K; Department of Brain Sciences, Imperial College London, London, UK.; UK Dementia Research Institute Centre for Care Research and Technology, London, UK., Orton L; Department of Brain Sciences, Imperial College London, London, UK.; Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK., Friedland D; Department of Brain Sciences, Imperial College London, London, UK., Coady E; Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK.; Department of Bioengineering, Imperial College London, London, UK., Laban R; UK Dementia Research Institute at UCL, London, UK.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK., Veleva E; UK Dementia Research Institute at UCL, London, UK.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK., Heslegrave AJ; UK Dementia Research Institute at UCL, London, UK.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK., Zetterberg H; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.; Institute of Neuroscience and Physiology, Goteborgs Universitet, Goteborg, Sweden., Schofield S; National Heart and Lung Institute, Imperial College London, London, UK., Fear NT; King's Centre for Military Health Research, King's College London, London, UK.; Academic Department for Military Mental Health, King's College London, London, UK., Boos CJ; Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK.; Faculty of Health & Social Sciences, Bournemouth University, Poole, UK., Bull AMJ; Department of Bioengineering, Imperial College London, London, UK.; Centre for Injury Studies, Imperial College London, London, UK., Bennett A; Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK.; Department of Bioengineering, Imperial College London, London, UK., Sharp DJ; Department of Brain Sciences, Imperial College London, London, UK david.sharp@imperial.ac.uk.; Care Research & Technology, UK Dementia Research Institute, London, UK.

Publikováno v: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Oct 11. Date of Electronic Publication: 2024 Oct 11.

Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes.

Autor: Zarkali A; Dementia Research Centre, Institute of Neurology, University College London, London WC1N 3AR, UK., Hannaway N; Dementia Research Centre, Institute of Neurology, University College London, London WC1N 3AR, UK., McColgan P; Huntington's Disease Centre, Institute of Neurology, University College London, London WC1B 5EH, UK., Heslegrave AJ; UK DRI Fluid Biomarker Lab and Biomarker Factory, University College London, London WC1E 6BT, UK., Veleva E; UK DRI Fluid Biomarker Lab and Biomarker Factory, University College London, London WC1E 6BT, UK., Laban R; UK DRI Fluid Biomarker Lab and Biomarker Factory, University College London, London WC1E 6BT, UK., Zetterberg H; Dementia Research Centre, Institute of Neurology, University College London, London WC1N 3AR, UK.; UK DRI Fluid Biomarker Lab and Biomarker Factory, University College London, London WC1E 6BT, UK., Lees AJ; Reta Lila Weston Institute of Neurological Studies, University College London, London WC1N 1PJ, UK., Fox NC; Dementia Research Centre, Institute of Neurology, University College London, London WC1N 3AR, UK.; National Hospital for Neurology and Neurosurgery, University College London Hospitals, London WC1N 3BG, UK., Weil RS; Dementia Research Centre, Institute of Neurology, University College London, London WC1N 3AR, UK.; National Hospital for Neurology and Neurosurgery, University College London Hospitals, London WC1N 3BG, UK.; Movement Disorders Centre, University College London, London WC1N 3BG, UK.; The Wellcome Centre for Human Neuroimaging, Institute of Neurology, University College London, London WC1N 3AR, UK.

Publikováno v: Brain communications [Brain Commun] 2024 Apr 16; Vol. 6 (3), pp. fcae130. Date of Electronic Publication: 2024 Apr 16 (Print Publication: 2024).

Alzheimer's disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI.

Autor: Graham N; Brain Sciences, Imperial College London, London, UK.; UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK., Zimmerman K; Brain Sciences, Imperial College London, London, UK.; UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK., Heslegrave AJ; UK Dementia Research Institute, University College London, London, UK., Keshavan A; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Moro F; Laboratory of Acute Brain Injury and Neuroprotection, Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.; Dipartimento di Anestesia e Rianimazione, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Abed-Maillard S; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Bernini A; Department of Clinical Neurosciences, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Dunet V; Department of Medical Radiology, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Garbero E; Laboratory of Clinical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy., Nattino G; Laboratory of Clinical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy., Chieregato A; Terapia Intensiva ad indirizzo Neurologico & Neurochirurgico, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Fainardi E; Department of Experimental and Clinical Sciences, Careggi University Hospital and University of Firenze, Florence, Italy., Baciu C; Terapia Intensiva ad indirizzo Neurologico & Neurochirurgico, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Gradisek P; Clinical Department of Anaesthesiology and Intensive Therapy, University Medical Center, Ljubljana, Slovenia., Magnoni S; Department of Anesthesia and Intensive Care, Santa Chiara Hospital, Trento, Italy., Oddo M; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Directorate for Innovation and Clinical Research, CHUV Lausanne University Hospital, Lausanne, Switzerland., Bertolini G; Laboratory of Clinical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy., Schott JM; UK Dementia Research Institute, University College London, London, UK.; Dementia Research Centre and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK., Zetterberg H; UK Dementia Research Institute, University College London, London, UK.; Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Sharp D; Brain Sciences, Imperial College London, London, UK david.sharp@imperial.ac.uk.; UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK.

Publikováno v: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Mar 13; Vol. 95 (4), pp. 356-359. Date of Electronic Publication: 2024 Mar 13.

Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials.

Autor: Street D; University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 OQQ, UK., Jabbari E; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Movement Disorders Centre, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Costantini A; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Movement Disorders Centre, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Jones PS; University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 OQQ, UK., Holland N; University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 OQQ, UK., Rittman T; University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 OQQ, UK., Jensen MT; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Movement Disorders Centre, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Chelban V; Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Neurobiology and Medical Genetics Laboratory, 'Nicolae Testemitanu' State University of Medicine and Pharmacy, Chisinau 2004, Republic of Moldova., Goh YY; Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Guo T; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Heslegrave AJ; Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; UK Dementia Research Institute, University College London, London, W1T 7NF, UK., Roncaroli F; Geoffrey Jefferson Brain Research Centre, Division of Neuroscience, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M6 8HD, UK., Klein JC; Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK., Ansorge O; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK., Allinson KSJ; University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 OQQ, UK., Jaunmuktane Z; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Queen Square Brain Bank for Neurological Disorders, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Reta Lila Weston Institute, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Revesz T; Queen Square Brain Bank for Neurological Disorders, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Reta Lila Weston Institute, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Warner TT; Queen Square Brain Bank for Neurological Disorders, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Reta Lila Weston Institute, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Lees AJ; Queen Square Brain Bank for Neurological Disorders, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Reta Lila Weston Institute, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Zetterberg H; Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; UK Dementia Research Institute, University College London, London, W1T 7NF, UK.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 431 30 Mölndal, Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salhgrenska Academy at the University of Gothenburg, 413 45 Goteborg, Sweden.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Shatin, N.T., Hong Kong, China., Russell LL; Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Bocchetta M; Centre for Cognitive and Clinical Neuroscience, Division of Psychology, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UB8 3PH, UK.; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK., Rohrer JD; Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Burn DJ; Faculty of Medical Sciences, Newcastle University, Newcastle, NE2 4HH, UK., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle, NE4 5PL, UK., Gerhard A; Division of Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, N20 3LJ, UK.; Departments of Geriatric Medicine and Nuclear Medicine, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, 45356 Essen, Germany., Kobylecki C; Division of Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, N20 3LJ, UK.; Department of Neurology, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, Salford, M13 9NQ, UK., Leigh PN; Department of Neuroscience, Brighton and Sussex Medical School, Brighton, BN1 9PX, UK., Church A; Department of Neurology, Royal Gwent Hospital, Newport, NP20 2UB, UK., Hu MTM; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.; Department of Physiology, Anatomy and Genetics, Oxford Parkinson's Disease Centre, University of Oxford, Oxford, OX1 3QU, UK., Houlden H; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Movement Disorders Centre, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Morris H; Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Movement Disorders Centre, University College London, Queen Square Institute of Neurology, London, WC1N 3BG, UK., Rowe JB; University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 OQQ, UK.; Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, CB2 7EF, UK.

Publikováno v: Brain : a journal of neurology [Brain] 2023 Aug 01; Vol. 146 (8), pp. 3232-3242.